



**Contact Information:**

Sherri Antoniak  
V.P. Corporate Development  
Naviscan PET Systems, Inc  
858-587-3641 ext. 113

**Naviscan PET Systems, Inc. Announces the Launch of the PEM Flex™ Solo II,  
a New High Resolution Scanner with PEMView™ Software**

**Chicago, IL** – November 27, 2006 - Naviscan PET Systems, Inc., a privately held company that manufactures and develops high-resolution PET scanners, announced today at the RSNA, the launch of its second generation PEM device—the PEM Flex *Solo II*.

Photonics improvements in the new *Solo II* yields higher count rate sensitivity while maintaining resolution capabilities of 1.5–2 mm. In addition, the *Solo II* adds an articulating arm, a motorized C-arm and compression capability, enabling technologists to more easily position patients for optimal views and improved chest wall access.

Also featured at the RSNA is PEMView, a companion image viewing and interpretation software. PEMView incorporates user-configurable image analysis tools as well as an embedded lexicon for effortless, standardized report generation. PEMView is the first of its kind web-based system, allowing for flexible workflow options.

“PEM technology has been highly successful in identifying additional disease in the same and opposite breast and provides excellent sensitivity, improved specificity and ease of interpretation for the technician” said Kathy Schilling, M.D., Medical Director of Breast Imaging and Intervention at the Center for Breast Care at the Boca Raton Community Hospital. Dr. Schilling is currently studying breast PEM to breast MRI and whole-body PET in the pre-op staging of patients with recently diagnosed invasive or non-invasive breast cancer. Preliminary results demonstrate that PEM is equal to MRI in the identification of the index lesion except in one case of the 18 studied.

Dr. Judy Kalinyak, M.D, Ph.D. from Hershey Medical School in Pennsylvania specializes in nuclear medicine and recently joined Naviscan as Medical Director. “We are very excited about the clinical trials with PEM in 2007. I believe it will change how we screen and diagnose breast cancer, specifically in the *in situ* stage, thereby reducing morbidity and mortality.”

Naviscan PET Systems, Inc. is the first company to obtain FDA clearance of a high-resolution PET scanner designed to image small body parts. The device was developed to help physicians and researchers diagnose and locate cancer, guide interventions, and advance new clinical therapies.

Studies have shown the PEM Flex system's sensitivity and specificity for characterizing suspicious lesions are both greater than 90%. The system has a positive predictive value of 92% for identifying breast cancer.\*

Naviscan's most recent investors include Sanderling Ventures in San Diego and San Mateo, and The Mayo Foundation for Medical Education and Research in Rochester, Minnesota.

\* Source: Wendie Berg, MD, PhD, et.al., "High Resolution Fluorodeoxyglucose Positron Emission Tomography with Compression ("Positron Emission Mammography") is Highly Accurate in Depicting Primary Breast Cancer," The Breast Journal, July/August 2006, 12:4, pp 300-323.

### **About Naviscan PET Systems**

Naviscan PET Systems, Inc., founded in 1995, designs and develops compact, high-resolution positron emission tomography (PET) scanners that are intended to provide precise organ-specific imaging, guide radiological and surgical procedures, and minimally invasive therapy. Naviscan has developed PET scanners utilized in clinical research studies, funded in part by the National Institutes of Health, at leading academic institutions. Results of these studies have been published in numerous peer-reviewed journals. The Company is headquartered in San Diego, California.